Lite Strategy, Inc. (LITS) vs TELA Bio, Inc. (TELA)

A side-by-side comparison of Lite Strategy, Inc. and TELA Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

LITS

Lite Strategy, Inc.

$48M

$1.41HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

TELA

TELA Bio, Inc.

$49M

$1.09HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — LITS vs TELA

growth of $100 · dividends reinvested · last 1y

LITS -69.1% (-69.1%/yr)TELA -30.9% (-30.9%/yr)TELA compounded faster over this window

LITS TELA

LITS vs TELA: by the numbers

•TELA is the larger company ($49M vs $48M market cap).
•Both run net losses; LITS's is the smaller (0.00% vs -51.53% net margin).

Metrics side by side

Valuation

Metric	LITS	TELA
P/S ratio	N/A	0.61
P/B ratio	1.15	N/A

Profitability

Metric	LITS	TELA
Gross margin	0.00%	67.81%
Operating margin	0.00%	-42.56%
Net margin	0.00%	-51.53%
ROE	-170.94%	N/A
ROIC	-30.75%	-80.88%

Growth (annualized)

Metric	LITS	TELA
Revenue CAGR (5Y)	N/A	26.77%
Total return CAGR (5Y)	N/A	-38.71%

Go deeper

Full LITS analysis Full TELA analysis Interactive comparison tool

Dig into the metrics

Lite Strategy ROE TELA Bio ROE Lite Strategy operating margin TELA Bio operating margin Lite Strategy revenue growth TELA Bio revenue growth Lite Strategy free cash flow TELA Bio free cash flow

Lite Strategy & TELA Bio appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.